Wednesday, 28 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Caplin Point Laboratories Business Update

Caplin Point Laboratories completed an unannounced US FDA inspection at its subsidiary's facility. The company received 10 procedural observations and will respond within the stipulated timeframe.

Source

BSE filing, NSE: CAPLIPOINT. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Caplin Point Laboratories Ltd: key numbers

Share price
₹2,362.80
Market cap
₹17,960 Cr
Revenue (annual)
₹2,187 Cr
Net profit (annual)
₹641.2 Cr
P/E (TTM)
27.0×Sector 46.1×
Promoter holding
70.57%+0.00% QoQ
FII holding
5.72%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Caplin Point Laboratories Ltd

All →

Other business update announcements

All →